Genflow Biosciences (LSE:GENF), a longevity-focused biotech developing therapies based on a centenarian-derived SIRT6 gene variant, said its US patent application covering the use of that variant in liver disease has been published by the US Patent and Trademark Office.
The application, US 2026/0199524 A1, covers the use of the company's SIRT6 variant (N308K/A313S) in preventing or treating non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Publication is a procedural step and does not itself constitute a grant.
Separately, the USPTO has granted Track One prioritized examination for Genflow's foundational SIRT6 compound-of-matter patent application, a filing exclusively licensed to the company from a group including the University of Rochester, Columbia University and Albert Einstein College of Medicine.
Track One status speeds up examination but does not guarantee a grant or determine the scope of any eventual claims.
The equivalent foundational application is also progressing in Canada, where a request for examination has been filed.
In Europe, the corresponding application is at an advanced stage before the European Patent Office, with Genflow awaiting a formal communication under Rule 71(3) EPC that typically precedes grant.
"Our foundational SIRT6c family, which is exclusively licensed to Genflow, seeks broad protection for the variant, while our Company-owned MASH family adds indication-specific claims," said chief executive Dr Eric Leire.
News Intelligence what this means for the company
Genflow advanced its SIRT6 patent portfolio with a US publication covering its proprietary variant in liver disease and accelerated examination status for its foundational compound patent in the US, while the European equivalent awaits a formal communication that typically precedes grant. Patent publication and Track One prioritization are procedural milestones that do not guarantee grants or claim scope, and Genflow's cash position at year-end 2025 was £111,792—making IP protection critical to its near-term value proposition.
Patent advancement reduces near-term IP risk for Genflow's core SIRT6 platform, but publication and prioritization remain procedural steps short of grant. The company's minimal cash reserves mean IP protection and non-dilutive funding (such as the Wallonia grant tranche received in early 2026) remain essential to runway.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
